fda reconsiders tirzepatide In blow to compounders, reaffirms shortage is over The Tirzepatide Shortage Is Over:

Supplementary material The Supplementary Material for this article can be found online at: Supplementary Table 1 Clinical characteristics and laboratory findings of study participants at baseline and 12 months after GLP-1 receptor agonist initiation

Here are some anecdotal comments from users on Reddit: A patient who jumped to 1.7 mg from 0.5 mg experienced severe nausea, vomiting, diarrhea, and sulfur burps, and decided to stay on the same dose to avoid the risk of further serious side effects

This evidence gap means clinical decisions rely on theoretical risk assessment, gestational timing of exposure, and individual maternal health factors rather than definitive safety data

A change in appearance signals oxidation or bacterial contamination and means the medication should not be injected